Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
EU5 Market Access Opportunities and Barriers for Outpatient Parenteral Antibiotic Therapy| Physician & Payer Forum | EU5 | 2015
Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do…
Gram-Negative Infections in the Cost-Constrained | Physician & Payer Forum | EU5 | 2015
Market Access Opportunities for Novel Therapies Targeting Multi-Drug-Resistant Pathogens Hospital-treated Gram-negative infections (GNIs) are becoming increasingly difficult to treat given rising…
Monoclonal Antibodies for the Treatment and Prophylaxis of Infectious Diseases: Development Opportunities for Novel Antibacterial and Antiviral Biologics
The past two decades have seen the arrival of revolutionary new biologic therapies for the treatment of numerous diseases, including inflammatory, hematologic, and malignant conditions. The…
Hepatitis C Virus (Positioning of Current and Emerging HCV Regimens)| Physician & Payer Forum | Latin America | 2015
Tackling the Market Access Challenges in Brazil, Mexico, and Argentina Increases in seroprevalent cases of hepatitis C virus (HCV), disease awareness, and patient access to HCV treatment…
Clostridium difficile Infections (Severe and Severe Recurrent)/Clostridium difficile-Associated Diarrhea | Decision Base | US | 2015
What Clinical Improvements Will Differentiate Emerging Therapies in a Market with High Unmet Need and Rising Use of Microbiome-Based Treatments? Clostridium difficile infection (CDI) and…
Gram-Negative Infections due to Carbapenem-Resistant Organisms | Decision Base | US | 2015
The Alarming Scarcity of Treatment Options for These Pathogens Presents an Attractive Market Opportunity for Novel Antibiotics The carbapenems are a class of potent gram-negative antibiotics…
